Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs BI 655130 (Primary)
- Indications Palmoplantar pustulosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 17 Jul 2018 According to EudraCT record, this trial has been completed in Denmark.
- 20 Mar 2018 Planned End Date changed from 24 Oct 2018 to 5 Nov 2018.
- 20 Mar 2018 Planned primary completion date changed from 4 Jul 2018 to 9 Jul 2018.